European Respiratory Society statement on frailty in adults with chronic lung disease

Christian R Osadnik; Lisa J Brighton; Chris Burtin; Matteo Cesari; Lies Lahousse; Will D C Man; Alessandra Marengoni; Andreja Sajnic; Jonathan P Singer; Lies Ter Beek; Ioanna Tsiligianni; Janos T Varga; Stefano Pavanello; Matthew Maddocks

doi:10.1183/13993003.00442-2023

European Respiratory Society statement on frailty in adults with chronic lung disease

Christian R Osadnik, Lisa J Brighton, Chris Burtin, Matteo Cesari, Lies Lahousse, Will D C Man, Alessandra Marengoni, Andreja Sajnic, Jonathan P Singer, Lies Ter Beek, Ioanna Tsiligianni, Janos T Varga, Stefano Pavanello, Matthew Maddocks

Research output: Contribution to Journal › Article › Academic › peer-review

40 Downloads (Pure)

Abstract

Frailty is a complex, multidimensional syndrome characterised by a loss of physiological reserves that increases a person's susceptibility to adverse health outcomes. Most knowledge regarding frailty originates from geriatric medicine, however, awareness of its importance as a treatable trait for people with chronic respiratory disease (including asthma, COPD and interstitial lung disease) is emerging. A clearer understanding of frailty and its impact in chronic respiratory disease is a pre-requisite to optimise clinical management in the future. This unmet need underpins the rationale for undertaking the present work.This European Respiratory Society Statement synthesises current evidence and clinical insights from international experts and people affected by chronic respiratory conditions regarding frailty in adults with chronic respiratory disease. The scope includes coverage of frailty within international respiratory guidelines, prevalence and risk factors, review of clinical management options (including comprehensive geriatric care, rehabilitation, nutrition, pharmacological and psychological therapies), and identification of evidence gaps to inform future priority areas of research. Frailty is under-represented in international respiratory guidelines, despite being common and related to increased hospitalisation and mortality. Validated screening instruments can detect frailty to prompt comprehensive assessment and personalised clinical management. Clinical trials targeting people with chronic respiratory disease and frailty are needed.

Original language	English
Article number	2300442
Pages (from-to)	1-27
Number of pages	27
Journal	European Respiratory Journal
Volume	62
Issue number	2
Early online date	17 Aug 2023
DOIs	https://doi.org/10.1183/13993003.00442-2023
Publication status	Published - Aug 2023

Bibliographical note

Funding

Conflict of interest: The task force members report no conflicts of interest for the present work, but acknowledge the following roles and funding sources during the conduct of this work. C.R. Osadnik received a Rebecca L. Cooper Medical Research Foundation project grant (2020–21) and an education grant from GSK Australia, paid to his institution, and delivered an educational lecture for Novartis Australia, all outside of the present work. L.J. Brighton is supported by the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust, and is funded by an Economic and Social Research Council Post-Doctoral Fellowship (ES/X005259/1). L. Lahousse reports external expert consultation for AstraZeneca and lectures for Chiesi and IPSA vzw, a non-profit organisation facilitating lifelong learning for healthcare providers, (to be) paid to her institution, outside this manuscript. W.D.C. Man is supported by National Institute for Health and Care Research (NIHR) Research for Patient Benefit awards (PB-PG-0816-20022 and PB-PG-0317-20032) and a NIHR Artificial Intelligence Award (AI_AWARD02204). A. Marengoni received fees for lectures provided to Vyvamed and Oliba. A. Sajnic reports advisory board membership for AstraZeneca and delivery of a lecture for Roche. J.P. Singer reports funding (NHLBI U01HL163242, U01HL145435, R01HL134851) and scientific advisory board membership for Altavant Sciences and Mallinckrodt Pharmaceuticals. I. Tsiligianni reports grants/advisory boards all unrelated to the current work from Novartis, GSK, Boehringer Ingelheim, AstraZeneca and Chiesi. J.T. Varga reports unrelated grants/advisory boards from Chiesi and Boehringer Ingelheim. S. Pavanello is president of Unione Trapiantati Polmone, Padua, Italy. M. Maddocks is supported by a National Institute for Health and Care Research (NIHR) Career Development Fellowship (CDF-2017–10-009) and the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust. The remaining authors have no potential conflicts of interest to disclose.

Funders	Funder number
NIHR ARC
King's College Hospital NHS Foundation Trust
Economic and Social Research Council	ES/X005259/1
National Institute for Health and Care Research	CDF-2017–10-009, PB-PG-0816-20022, AI_AWARD02204, PB-PG-0317-20032
National Institute for Health Research Applied Research Collaboration South London

Access to Document

10.1183/13993003.00442-2023

European Respiratory Society statement on frailty in adults with chronic lung diseaseFinal published version, 1.41 MBLicence: Article 25fa Dutch Copyright Act

Persistent URL (handle)

Copy link address

Cite this

Osadnik, C. R., Brighton, L. J., Burtin, C., Cesari, M., Lahousse, L., Man, W. D. C., Marengoni, A., Sajnic, A., Singer, J. P., Ter Beek, L., Tsiligianni, I., Varga, J. T., Pavanello, S., & Maddocks, M. (2023). European Respiratory Society statement on frailty in adults with chronic lung disease. European Respiratory Journal, 62(2), 1-27. Article 2300442. https://doi.org/10.1183/13993003.00442-2023

@article{92a2bb9df35548a9a37f5f3b72bb261a,

title = "European Respiratory Society statement on frailty in adults with chronic lung disease",

abstract = "Frailty is a complex, multidimensional syndrome characterised by a loss of physiological reserves that increases a person's susceptibility to adverse health outcomes. Most knowledge regarding frailty originates from geriatric medicine, however, awareness of its importance as a treatable trait for people with chronic respiratory disease (including asthma, COPD and interstitial lung disease) is emerging. A clearer understanding of frailty and its impact in chronic respiratory disease is a pre-requisite to optimise clinical management in the future. This unmet need underpins the rationale for undertaking the present work.This European Respiratory Society Statement synthesises current evidence and clinical insights from international experts and people affected by chronic respiratory conditions regarding frailty in adults with chronic respiratory disease. The scope includes coverage of frailty within international respiratory guidelines, prevalence and risk factors, review of clinical management options (including comprehensive geriatric care, rehabilitation, nutrition, pharmacological and psychological therapies), and identification of evidence gaps to inform future priority areas of research. Frailty is under-represented in international respiratory guidelines, despite being common and related to increased hospitalisation and mortality. Validated screening instruments can detect frailty to prompt comprehensive assessment and personalised clinical management. Clinical trials targeting people with chronic respiratory disease and frailty are needed.",

author = "Osadnik, {Christian R} and Brighton, {Lisa J} and Chris Burtin and Matteo Cesari and Lies Lahousse and Man, {Will D C} and Alessandra Marengoni and Andreja Sajnic and Singer, {Jonathan P} and {Ter Beek}, Lies and Ioanna Tsiligianni and Varga, {Janos T} and Stefano Pavanello and Matthew Maddocks",

note = "Copyright {\textcopyright}The authors 2023. For reproduction rights and permissions contact [email protected].",

year = "2023",

month = aug,

doi = "10.1183/13993003.00442-2023",

language = "English",

volume = "62",

pages = "1--27",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

Osadnik, CR, Brighton, LJ, Burtin, C, Cesari, M, Lahousse, L, Man, WDC, Marengoni, A, Sajnic, A, Singer, JP, Ter Beek, L, Tsiligianni, I, Varga, JT, Pavanello, S & Maddocks, M 2023, 'European Respiratory Society statement on frailty in adults with chronic lung disease', European Respiratory Journal, vol. 62, no. 2, 2300442, pp. 1-27. https://doi.org/10.1183/13993003.00442-2023

TY - JOUR

T1 - European Respiratory Society statement on frailty in adults with chronic lung disease

AU - Osadnik, Christian R

AU - Brighton, Lisa J

AU - Burtin, Chris

AU - Cesari, Matteo

AU - Lahousse, Lies

AU - Man, Will D C

AU - Marengoni, Alessandra

AU - Sajnic, Andreja

AU - Singer, Jonathan P

AU - Ter Beek, Lies

AU - Tsiligianni, Ioanna

AU - Varga, Janos T

AU - Pavanello, Stefano

AU - Maddocks, Matthew

PY - 2023/8

Y1 - 2023/8

N2 - Frailty is a complex, multidimensional syndrome characterised by a loss of physiological reserves that increases a person's susceptibility to adverse health outcomes. Most knowledge regarding frailty originates from geriatric medicine, however, awareness of its importance as a treatable trait for people with chronic respiratory disease (including asthma, COPD and interstitial lung disease) is emerging. A clearer understanding of frailty and its impact in chronic respiratory disease is a pre-requisite to optimise clinical management in the future. This unmet need underpins the rationale for undertaking the present work.This European Respiratory Society Statement synthesises current evidence and clinical insights from international experts and people affected by chronic respiratory conditions regarding frailty in adults with chronic respiratory disease. The scope includes coverage of frailty within international respiratory guidelines, prevalence and risk factors, review of clinical management options (including comprehensive geriatric care, rehabilitation, nutrition, pharmacological and psychological therapies), and identification of evidence gaps to inform future priority areas of research. Frailty is under-represented in international respiratory guidelines, despite being common and related to increased hospitalisation and mortality. Validated screening instruments can detect frailty to prompt comprehensive assessment and personalised clinical management. Clinical trials targeting people with chronic respiratory disease and frailty are needed.

AB - Frailty is a complex, multidimensional syndrome characterised by a loss of physiological reserves that increases a person's susceptibility to adverse health outcomes. Most knowledge regarding frailty originates from geriatric medicine, however, awareness of its importance as a treatable trait for people with chronic respiratory disease (including asthma, COPD and interstitial lung disease) is emerging. A clearer understanding of frailty and its impact in chronic respiratory disease is a pre-requisite to optimise clinical management in the future. This unmet need underpins the rationale for undertaking the present work.This European Respiratory Society Statement synthesises current evidence and clinical insights from international experts and people affected by chronic respiratory conditions regarding frailty in adults with chronic respiratory disease. The scope includes coverage of frailty within international respiratory guidelines, prevalence and risk factors, review of clinical management options (including comprehensive geriatric care, rehabilitation, nutrition, pharmacological and psychological therapies), and identification of evidence gaps to inform future priority areas of research. Frailty is under-represented in international respiratory guidelines, despite being common and related to increased hospitalisation and mortality. Validated screening instruments can detect frailty to prompt comprehensive assessment and personalised clinical management. Clinical trials targeting people with chronic respiratory disease and frailty are needed.

U2 - 10.1183/13993003.00442-2023

DO - 10.1183/13993003.00442-2023

M3 - Article

C2 - 37414420

SN - 0903-1936

VL - 62

SP - 1

EP - 27

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

M1 - 2300442

ER -

European Respiratory Society statement on frailty in adults with chronic lung disease

Abstract

Bibliographical note

Funding

Access to Document

Persistent URL (handle)

Fingerprint

Cite this